APC anti-human CD3 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation, and activation of T lymphocytes^4-7. The HIT3a antibody is able to stimulate T cell activation. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300314). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Sedelies KA, et al. 2004. J. Biol. Chem. 279:26581. (Activ)
5. Rivollier A, et al. 2004. Blood 104:4029. (Activ)
6. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Activ)
7. Smeltz RB. 2007. J. Immunol. 178:4786. (Activ)

Product Citations

1. Pan J, et al. 2021. J Cell Mol Med. 25:1089. PubMed
2. Liu C, et al. 2022. Front Immunol. 13:1039631. PubMed
3. Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed
4. Tunali G, et al. 2023. J Clin Invest. :. PubMed
5. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
6. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
7. Tate T, et al. 2023. Cancers (Basel). 15:. PubMed
8. Yuan X, et al. 2023. Oncoimmunology. 12:2219544. PubMed
9. Zeng W, et al. 2017. Front Immunol. 0.806944444. PubMed
10. Lopez-Vergès S, et al. 2010. Blood. 116:3865. PubMed
11. Yomogida K, et al. 2012. Cytokine. 58:431. PubMed
12. Merugu S, et al. 2020. Methods Enzymol. 639:289. PubMed
13. Morton JJ, et al. 2018. Mol Carcinog. 57:1651. PubMed
14. Ge Y, et al. 2019. J Immunol. 203:2827. PubMed
15. Huang C, et al. 2020. Theranostics. 10:10498. PubMed
16. Alsaleh G, et al. 2020. Elife. 9: . PubMed
17. Chulpanova DS, et al. 2020. Bioengineering (Basel). 7:00. PubMed
18. Cao Y, et al. 2021. Cell Res. 31:732. PubMed
19. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
20. Zhang J, et al. 2022. Nature. 609:369. PubMed
21. Domenis R, et al. 2017. PLoS One. 10.1371/journal.pone.0169932. PubMed
22. , et al. 2021. Eur J Immunol. 51:2708. PubMed
23. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
24. Morton JJ, et al. 2020. Molecular Cancer Research. 19(2):346-357. PubMed
25. Roider T, et al. 2021. Blood Adv. 5:5060. PubMed
26. Wang L, et al. 2021. Microbiol Spectr. 9:e0124621. PubMed
27. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
28. Mlynska A, et al. 2020. Am J Reprod Immunol. 84:e13244. PubMed
29. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
30. Yin S, et al. 2015. Sci Rep. 5: 14432. PubMed
31. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
32. Hu Q, et al. 2021. Nat Commun. 12:2186. PubMed
33. Reyes M, et al. 2021. Sci Transl Med. 13:. PubMed
34. Lee YG, et al. 2019. Nat Commun. 10:2681. PubMed
35. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
36. Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed
37. Hu JF, et al. 2022. Front Immunol. 13:958960. PubMed
38. Li X, et al. 2021. Front Oncol. 11:703087. PubMed
39. Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed
40. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
41. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
42. Jiang L, et al. 2019. Sci Rep. 9:3705. PubMed
43. Wang Z, et al. 2018. Front Immunol. 9:1239. PubMed
44. Zhong W, et al. 2022. Front Immunol. 13:1001255. PubMed
45. Mlynska A, et al. 2019. Oncol Rep. 41:1238. PubMed

RRID

AB_314047 (BioLegend Cat. No. 300311)
AB_314047 (BioLegend Cat. No. 300312)

Antigen Details

Structure

Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD

Distribution

Mature T and NK-T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats